Nuvation Bio Inc. Increase (Decrease) in Accounts Receivable
Nuvation Bio Inc. (NUVB) reported Increase (Decrease) in Accounts Receivable of $11.75 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2026-08-06
- Nuvation Bio Inc. increase (decrease) in accounts receivable for the quarter ending 2026-06-30 was $5.10M, a 123.42% increase year-over-year.
- Nuvation Bio Inc. increase (decrease) in accounts receivable for the quarter ending 2026-03-31 was $6.65M.
- Nuvation Bio Inc. increase (decrease) in accounts receivable for the quarter ending 2025-12-31 was $7.75M, a 38.52% decline year-over-year.
- Nuvation Bio Inc. increase (decrease) in accounts receivable for the quarter ending 2025-09-30 was $5.63M.
- Nuvation Bio Inc. increase (decrease) in accounts receivable for fiscal 2025 was $3.35M, a 73.64% decline from fiscal 2024.
- Nuvation Bio Inc. increase (decrease) in accounts receivable for fiscal 2024 was $12.72M.
- Nuvation Bio Inc. increase (decrease) in accounts receivable for fiscal 2023 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $11.75M 10-Q · filed 2026-08-06 | $19.50M derived: sum of 3 quarters · filed 2026-08-06 | $25.13M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $6.65M 10-Q · filed 2026-05-04 | $14.40M derived: sum of 2 quarters · filed 2026-05-04 | $20.03M derived: sum of 3 quarters · filed 2026-05-04 | $22.31M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $7.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $13.38M derived: sum of 2 quarters · filed 2026-03-02 | $15.67M derived: sum of 3 quarters · filed 2026-08-06 | $3.35M 10-K · filed 2026-03-02 |
| 2025-09-30 | $5.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $7.91M derived: sum of 2 quarters · filed 2026-08-06 | -$4.40M 10-Q · filed 2025-11-03 | $8.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$10.03M 10-Q · filed 2026-08-06 | $2.58M derived: sum of 3 quarters · filed 2026-08-06 | $2.58M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$12.31M 10-Q · filed 2026-05-04 | $297.00K derived: sum of 2 quarters · filed 2026-05-04 | $292.00K derived: sum of 3 quarters · filed 2026-05-04 | $409.00K derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | $12.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $12.61M derived: sum of 2 quarters · filed 2026-03-02 | $12.72M derived: sum of 3 quarters · filed 2026-03-02 | $12.72M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$5.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | $112.00K derived: sum of 2 quarters · filed 2025-11-03 | $112.00K 10-Q · filed 2025-11-03 | $112.00K derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $117.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $117.00K 10-Q · filed 2025-08-07 | $117.00K derived: sum of 3 quarters · filed 2025-08-07 | $117.00K derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-07 | $0.00 derived: sum of 2 quarters · filed 2025-05-07 | $0.00 derived: sum of 3 quarters · filed 2025-05-07 | |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $0.00 derived: sum of 2 quarters · filed 2025-03-06 | $0.00 10-K · filed 2025-03-06 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $0.00 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | $0.00 10-Q · filed 2024-08-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |